Nanoform Interim Report January – June 2021 di.se - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from di.se Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ The strong momentum continues: Additional line capacity, more projects, new clients, the number of employees crosses 100, while the gross.
Nanoform Interim Report January – March (Q1) 2021
Nanoform
Company Announcement
Nanoform Interim Report January – March (Q1) 2021
Strong momentum continues: three new non-GMP lines commissioned, four new clients signed, and six new customer PoC projects commenced. In addition, positive results from first clinical study announced, two near-term business targets achieved (“First Biologics PoC in 2021” and “at least three new non-GMP lines in 2021”), next generation STARMAP
® launched, EUR 40 million successfully raised and commercial teams in the US and the UK further strengthened.
1-3/2021 key financials
- Revenue EUR 278 thousand, growth + 85%, stemming from 14 different customer projects (EUR 150 thousand, 6 customer projects in 1-3/2020).
- The gross profit and gross margin improved to EUR 243 thousand and 88%, respectively (EUR 103 thousand, 68%).